Skip to main content
Clinical Trials/IRCT20131218015860N7
IRCT20131218015860N7RecruitingPhase 3

Evaluation of the effects of the cardioprotective diet on prevention of the incidence of cardiotoxicity in patients with breast cancer receiving Anthracycline

School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center,Shahid Behes0 sites60 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 65 years (—)
Sex
Female

Inclusion Criteria

  • Women age 18-65
  • Breast cancer (based on pathology response)
  • Candidate for chemotherapy including anthracyclines +/- trastuzumab
  • 25 =BMI = 19
  • Willingness to participate in the study

Exclusion Criteria

  • History of heart failure
  • History of coronary artery disease
  • Symptoms of heart failure (functional shortness of breath, orthopedics, PND)
  • Ejection Fraction less than or equal to 40
  • Use of beta-blockers or ACEI
  • Change the chemotherapy regimen for any reason
  • Unwillingness to continue the study
  • Follow less than 70% of trained dietary recommendations
  • History of liver disease (except grade 1 and 2 fatty liver)
  • History of kidney disease (other than history of urinary stones)
  • History of depression (taking antidepressants)
  • BMI greater than 25 and less than 19

Investigators

Sponsor
School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center,Shahid Behes

Similar Trials